Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

Did you experience any of the following side effects? (Check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Clozapine Associated With Risk of Hyperglycemia and Diabetes

Apr 9, 2004 |

Clozapine (Clozaril) is associated with a risk of hyperglycemia and diabetes, according to an alert released yesterday by MedWatch, the U.S. Food and Drug Administration (FDA) safety information and adverse event reporting program. The FDA and Novartis notified healthcare professionals last week of revisions to the warnings section of labeling for clozapine that describe the increased risk.

The FDA based its labeling change decision on a review of recent data related to the use of atypical antipsychotics and hyperglycemia. Although precise estimates are not available, epidemiologic studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients using these drugs. In March, Eli Lilly and Co. revised labeling for its atypical antipsychotic olanzapine (Zyprexa).

According to a letter to clinicians from Novartis, the relationship between atypical antipsychotic use and hyperglycemia is not fully understood, and the link is confounded by the possibility of increased background risk of diabetes mellitus in patients with schizophrenia as well by the increasing incidence of diabetes in the general population.

The FDA recommends that patients with diabetes starting on atypical antipsychotic drugs be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of treatment and periodically thereafter.

All patients receiving atypical antipsychotics should be monitored for symptoms of hyperglycemia (polydipsia, polyuria, polyphagia, and weakness). Those developing these symptoms during treatment should undergo fasting blood glucose testing.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo